Detalles de la búsqueda
1.
Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE).
J Eur Acad Dermatol Venereol
; 37(7): 1366-1374, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-36695074
2.
Development of the alopecia areata scale for clinical use: Results of an academic-industry collaborative effort.
J Am Acad Dermatol
; 86(2): 359-364, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34474079
3.
Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial.
J Am Acad Dermatol
; 78(6): 1156-1163, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29409914
4.
WITHDRAWN: Efficacy and safety of topical oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 2 phase 3, 29-day, randomized, controlled REVEAL trials.
J Am Acad Dermatol
; 2018 Jan 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-29409915
5.
Clinical Pharmacokinetics of Oxymetazoline Cream Following Topical Facial Administration for the Treatment of Erythema Associated With Rosacea.
J Drugs Dermatol
; 17(2): 213-220, 2018 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29462230
6.
Phase 2 Randomized, Dose-Ranging Study of Oxymetazoline Cream for Treatment of Persistent Facial Erythema Associated With Rosacea.
J Drugs Dermatol
; 17(3): 308-316, 2018 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29537449
7.
Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the Second REVEAL Trial.
J Drugs Dermatol
; 17(3): 290-298, 2018 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29537447
8.
Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the First REVEAL Trial.
J Drugs Dermatol
; 17(1): 97-105, 2018 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29320594
9.
Clinically Relevant Reduction in Persistent Facial Erythema of Rosacea on the First Day of Treatment With Oxymetazoline Cream 1.0.
J Drugs Dermatol
; 17(6): 621-626, 2018 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29879249
10.
Topical Oxymetazoline Cream 1.0% for Persistent Facial Erythema Associated With Rosacea: Pooled Analysis of the Two Phase 3, 29-Day, Randomized, Controlled REVEAL Trials
J Drugs Dermatol
; 17(11): 1201-1208, 2018 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30500142
11.
Safety and efficacy of bimatoprost solution 0.03% topical application in patients with chemotherapy-induced eyelash loss.
J Investig Dermatol Symp Proc
; 16(1): S73-6, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24326568
12.
Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment.
J Am Acad Dermatol
; 79(3): e57-e59, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29860043
13.
Apoptosis in the hair follicle.
J Invest Dermatol
; 126(2): 258-64, 2006 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-16418734
14.
Safety and Efficacy of Bimatoprost for Eyelash Growth in Postchemotherapy Subjects.
J Clin Aesthet Dermatol
; 8(4): 11-20, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26060513
15.
Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia.
Sci Transl Med
; 4(126): 126ra34, 2012 Mar 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-22440736
16.
Survivin in the human hair follicle.
J Invest Dermatol
; 127(2): 479-82, 2007 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-16946715
Resultados
1 -
16
de 16
1
Próxima >
>>